Duncan Bridgeman
|
Friday 14th November 2003 |
Text too small? |
However, a policy change in accounting for foreign exchange hedges made comparisons with the same period a year ago misleading.
F&P Healthcare shares traded early yesterday at $12.05, down 20c since the interim profit announcement on Wednesday.
While net profit fell to $25.2 million, revenue growth from new products climbed 27% in US dollar terms, pushing operating revenue up 3.8% to a record $104.9 million.
The company is forecasting full year revenue of between $US120 million ($193.5 million) and $US125 million.
ABN Amro said in a research note it was reviewing its target price of $13.14 and its add recommendation on the stock. The broking house noted that the company's new obstructive sleep apnoea (OSA) flow generators would be fully established in the second half of the current financial year while its new mask products should continue to increase consumables market sha
No comments yet
AGL - Accordant Group Limited announces CEO retirement
VCT - Results of annual shareholders' meeting
HGH - Heartland acknowledges TSB Section 95 Notice
TEM - Transaction in Own Shares
SKO - Serko announces CFO Transition
September 25th Morning Report
CCC - Cooks Coffee Company Appoints New Group Marketing Director
AIR - Air NZ 2026 Annual Shareholders' Meeting Materials
CVT - Annual Meeting, Director Nomination & Shareholder Proposal
TEM - Transaction in Own Shares